Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer
Athanassios Argiris(The University of Texas at San Antonio Health Science Center), Robert L. Ferris(University of Pittsburgh), Barton F. Branstetter(University of Pittsburgh Medical Center), William E. Gooding(UPMC Hillman Cancer Center), Donna M. Posluszny(Apple (Israel)), Dwight E. Heron(Bon Secours Mercy Health), Maria Vassilakopoulou(Yale University), Umamaheswar Duvvuri(City University of New York), John T. Flaherty(Johns Hopkins University), Gregory J. Kubicek(Cooper University Hospital), D.A. Clump(UPMC Hillman Cancer Center), S. Kim(University of Pittsburgh), James Ohr(University of Pittsburgh), Simion I. Chiosea(University of Pittsburgh), Julie E. Bauman(George Washington University), Jonas T. Johnson(University of Pittsburgh), Jennifer R. Grandis(University of California, San Francisco), Michael K. Gibson(Vanderbilt University)
Cited by 49
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688